Stable Frequencies of HLA-C*03:04/Peptide-Binding KIR2DL2/3+ Natural Killer Cells Following Vaccination
Standard
Stable Frequencies of HLA-C*03:04/Peptide-Binding KIR2DL2/3+ Natural Killer Cells Following Vaccination. / Ziegler, Maja Christiane; Grañana, Ferran Borràs; Garcia-Beltran, Wilfredo F; Schulze Zur Wiesch, Julian; Hoffmann, Christian; Rechtien, Anne; Lunemann, Sebastian; Altfeld, Marcus.
In: FRONT IMMUNOL, Vol. 9, 2018, p. 2361.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Stable Frequencies of HLA-C*03:04/Peptide-Binding KIR2DL2/3+ Natural Killer Cells Following Vaccination
AU - Ziegler, Maja Christiane
AU - Grañana, Ferran Borràs
AU - Garcia-Beltran, Wilfredo F
AU - Schulze Zur Wiesch, Julian
AU - Hoffmann, Christian
AU - Rechtien, Anne
AU - Lunemann, Sebastian
AU - Altfeld, Marcus
PY - 2018
Y1 - 2018
N2 - Inhibitory KIRs play a central role in regulating NK cell activity. KIR2DL2/3 bind to HLA-C molecules, but the modulation of these interactions by viral infections and presentation of viral epitopes is not well-understood. We investigated whether the frequencies of KIR2DL2/3+ NK cells recognizing HLA-C*03:04/viral peptide complexes were impacted by YFV vaccination or HIV-1 and HCV infection. Ex vivo HLA class I tetramer staining of primary human NK cells derived from YFV-vaccinated individuals, or HIV-1- or HCV-infected individuals revealed that the YFV/HLA-C*03:04-NS2A4-13-tetramer bound to a larger proportion of KIR2DL2/3+ NK cells compared to HIV-1/HLA-C*03:04-Gag296-304- or HCV/HLA-C*03:04-Core136-144-tetramers. The YFV/HLA-C*03:04-NS2A4-13-tetramer also exhibited a stronger avidity to KIR2DL2/3 compared to the other tested tetramers. The proportional frequencies of KIR2DL2/3+ NK cells binding to the three tested HLA-C*03:04 tetramers were identical between YFV-vaccinated individuals or HIV-1- or HCV-infected individuals, and remained stable following YFV vaccination. These data demonstrate consistent hierarchies in the frequency of primary KIR2DL2/3+ NK cells binding HLA-C*03:04/peptide complexes that were determined by the HLA-C-presented peptide and not modulated by the underlying viral infection or vaccination.
AB - Inhibitory KIRs play a central role in regulating NK cell activity. KIR2DL2/3 bind to HLA-C molecules, but the modulation of these interactions by viral infections and presentation of viral epitopes is not well-understood. We investigated whether the frequencies of KIR2DL2/3+ NK cells recognizing HLA-C*03:04/viral peptide complexes were impacted by YFV vaccination or HIV-1 and HCV infection. Ex vivo HLA class I tetramer staining of primary human NK cells derived from YFV-vaccinated individuals, or HIV-1- or HCV-infected individuals revealed that the YFV/HLA-C*03:04-NS2A4-13-tetramer bound to a larger proportion of KIR2DL2/3+ NK cells compared to HIV-1/HLA-C*03:04-Gag296-304- or HCV/HLA-C*03:04-Core136-144-tetramers. The YFV/HLA-C*03:04-NS2A4-13-tetramer also exhibited a stronger avidity to KIR2DL2/3 compared to the other tested tetramers. The proportional frequencies of KIR2DL2/3+ NK cells binding to the three tested HLA-C*03:04 tetramers were identical between YFV-vaccinated individuals or HIV-1- or HCV-infected individuals, and remained stable following YFV vaccination. These data demonstrate consistent hierarchies in the frequency of primary KIR2DL2/3+ NK cells binding HLA-C*03:04/peptide complexes that were determined by the HLA-C-presented peptide and not modulated by the underlying viral infection or vaccination.
KW - Flow Cytometry
KW - HLA-C Antigens/chemistry
KW - Humans
KW - Killer Cells, Natural/immunology
KW - Leukocytes, Mononuclear/immunology
KW - Multiprotein Complexes
KW - Peptides/chemistry
KW - Protein Binding
KW - Receptors, KIR2DL2/metabolism
KW - Receptors, KIR2DL3/metabolism
KW - Vaccination
KW - Vaccines/immunology
U2 - 10.3389/fimmu.2018.02361
DO - 10.3389/fimmu.2018.02361
M3 - SCORING: Journal article
C2 - 30386333
VL - 9
SP - 2361
JO - FRONT IMMUNOL
JF - FRONT IMMUNOL
SN - 1664-3224
ER -